← Back
NeuroTrials.ai
Neurology Clinical Trial Database

QALS

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify Phase III

Year of Publication: 2009

Authors: Petra Kaufmann, John L.P. Thompson, Gilberto Levy, ..., for the QALS Study Group

Journal: Annals of Neurology

Citation: Ann Neurol. 2009;66(2):235-244. doi:10.1002/ana.21743

Link: https://clinicaltrials.gov/ct2/show/NCT00243932


Clinical Question

Does high-dose Coenzyme Q10 (1,800 or 2,700 mg/day), an antioxidant and mitochondrial cofactor, show sufficient promise to warrant Phase III testing in patients with ALS?

Bottom Line

CoQ10 at 2,700 mg/day for 9 months showed insufficient promise to warrant Phase III testing. While the primary futility analysis did not definitively rule out proceeding to Phase III (p=0.14), a pre-specified sensitivity analysis (p=0.025) and secondary analyses showed no benefit. The result was sensitive to how deceased patients were scored on the ALSFRS-R. CoQ10 was safe and well-tolerated. The innovative two-stage adaptive design successfully minimized sample size requirements while providing definitive guidance against further development.

Major Points

  • Stage 1 dose selection: 2,700 mg/day selected over 1,800 mg/day based on lower mean 9-month ALSFRS-R decline (9.0 vs 10.9)
  • Stage 2 primary futility analysis: Mean ALSFRS-R decline was 8.8 (CoQ10) vs 9.4 (placebo); null hypothesis of ≥20% superiority not rejected (p=0.14)
  • Pre-specified sensitivity analysis with death score=16 (10th percentile): Declines were similar (8.5 vs 8.4), futility was declared (p=0.025)
  • Mortality during 9-month follow-up: 1 on CoQ10 vs 5 on placebo (not statistically significant); outlying values from deceased placebo patients drove apparent CoQ10 benefit in primary analysis
  • Median ALSFRS-R decline was slightly greater for CoQ10 than placebo, insensitive to outliers
  • Post hoc slope analysis consistent with futility (p=0.097)
  • No significant differences in secondary outcomes (FVC, SF-36 quality of life, fatigue severity)
  • CoQ10 plasma levels significantly increased from baseline in active groups but not placebo, confirming compliance and minimal drop-in
  • No difference in plasma levels between 1,800 and 2,700 mg doses, consistent with plateau effect
  • Innovative adaptive Phase II design required only 185 participants vs ~900 for conventional approach

Design

Study Type: Phase II, multicenter, randomized, stratified, placebo-controlled, double-blind, two-stage adaptive, bias-corrected, futility design

Randomization: 1

Blinding: Double-blind; identical wafers for active and placebo (yellow color, maple flavor); participants, investigators, and evaluators blinded

Enrollment Period: April 2005 to May 2007 (Stage 1: April 2005 to February 2006; Stage 2: February to May 2007)

Follow-up Duration: 9 months treatment + 1 month post-treatment safety follow-up

Centers: 19

Countries: United States

Sample Size: 185

Analysis: Intent-to-treat; Stage 1: selection procedure (no significance test) to identify preferred dose; Stage 2: one-sided futility test (α=0.10) with bias correction for carrying forward Stage 1 data; nearest-neighbor imputation for missing data (worst-case primary, best-case sensitivity); mixed effects model slope analysis (post hoc); ALSFRS-R reliability assessed


Inclusion Criteria

  • Age 21-85 years
  • Clinical diagnosis of definite, probable, or laboratory-supported probable ALS by El Escorial criteria
  • Sporadic or familial ALS
  • Forced vital capacity (FVC) ≥60% of predicted
  • Disease onset ≤5 years before study entry

Exclusion Criteria

  • FVC <60% of predicted
  • Severe medical illness
  • Disease onset >5 years before study entry

Arms

FieldStage 1: CoQ10 1,800 mg/dayStage 1 & 2: CoQ10 2,700 mg/dayControl
InterventionCoQ10 200 mg wafers, 3 wafers three times daily (1,800 mg/day total), chewable, maple-flavoredCoQ10 300 mg wafers, 3 wafers three times daily (2,700 mg/day total), chewable, maple-flavored; selected dose from Stage 1 for Stage 2 comparisonMatching placebo wafers identical in yellow color and maple flavor but without CoQ10, 3 wafers three times daily
Duration9 months9 months9 months

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Decline in ALSFRS-R score from baseline to 9 months (positive value indicates worsening); Stage 1: dose selection; Stage 2: futility test with null hypothesis that CoQ10 reduces mean decline by ≥20% vs placeboPrimary
FVC decline (% predicted) over 9 monthsSecondary0.17 (0.18)0.20 (0.15)0.27
SF-36 Physical Component Score (PCS) declineSecondary6.04 (6.85)4.22 (8.02)0.14
SF-36 Mental Component Score (MCS) declineSecondary5.01 (11.69)2.87 (11.78)0.27
Fatigue Severity Scale increaseSecondary0.88 (1.51)0.71 (1.21)0.45
Post hoc slope analysis (ALSFRS-R)SecondaryReferenceNot significantly different0.097 (one-sided, consistent with futility)
Any AEAdverse85.3% (64/75)84.0% (63/75)
FallAdverse22.7% (17/75)37.3% (28/75)
PainAdverse25.3% (19/75)29.3% (22/75)
NauseaAdverse21.3% (16/75)17.3% (13/75)
ConstipationAdverse13.3% (10/75)24.0% (18/75)
DiarrheaAdverse24.0% (18/75)10.7% (8/75)
Mood alterationAdverse9.3% (7/75)21.3% (16/75)
PEG placementAdverse13.3% (10/75)10.7% (8/75)
Any serious AEAdverse25.3% (19/75)24.0% (18/75)
Death (through 9 months)Adverse6.7% (5/75)4.0% (3/75, includes 2 during month 10 safety follow-up)NS
AEs possibly related to treatmentAdverse41.3% (31/75)42.7% (32/75)

Subgroup Analysis

Stage 1 dose selection showed 2,700 mg/day had lower mean ALSFRS-R decline than 1,800 mg/day (9.0 vs 10.9). However, plasma CoQ10 levels did not differ significantly between the two active doses, consistent with a plateau effect previously reported at 2,400 mg. Sensitivity analyses varying the death score from 0 to 16 showed futility (p<0.10) for 13 of 17 scores tested (scores 4-16), but not for scores 0-3.


Criticisms

  • Primary analysis result was highly sensitive to the choice of score assigned to deceased patients (0 vs 10th percentile vs other values)
  • More deaths occurred in placebo group (5 vs 1) driving apparent CoQ10 benefit; difference not statistically significant
  • Plasma CoQ10 levels did not differ between 1,800 and 2,700 mg doses, suggesting plateau effect and questioning whether higher doses achieve greater tissue penetration
  • Stage 1 dose selection did not include a head-to-head significance test, only a selection procedure
  • Gender imbalance in Stage 1 (71% male at 1,800 mg vs 43% at 2,700 mg)
  • No single best or correct score for deceased patients can be specified a priori for ALSFRS-R
  • Compliance by wafer count was only 71-73% for ≥80% consumption threshold
  • Oxidative stress biomarker (8OH2dG) results not available at time of publication
  • Study powered to detect 20% slowing in decline, which may be too ambitious; smaller effects could be missed
  • Short 9-month follow-up may miss delayed neuroprotective effects
  • Riluzole use differed between groups (76% CoQ10 vs 67% placebo)

Funding

NINDS R01 NS48555 (Thompson), NINDS R01 NS48125 (Kaufmann), K12RR017648 (Kaufmann), CTSA Award NIH 1 UL1 RR024156 (Columbia University), and additional GCRC support from multiple participating institutions

Based on: QALS (Annals of Neurology, 2009)

Authors: Petra Kaufmann, John L.P. Thompson, Gilberto Levy, ..., for the QALS Study Group

Citation: Ann Neurol. 2009;66(2):235-244. doi:10.1002/ana.21743

Content summarized and formatted by NeuroTrials.ai.